Aesthera vs Rimo: Same Model, Different Buyer
Rimo and Aesthera use the same commercial model: a flat fee, no revenue share, and the client owning the patients. Rimo's fee is not published, and it sells to D2C brands rather than med spas. The model is identical, the buyer is not.
This is the comparison where the two platforms agree most and the difference lies somewhere other than the pricing philosophy.
Where the two agree
Both charge a flat fee. Both state no revenue share. Both state that the client owns the patients and the data.
That matters more than it sounds. Several platforms on this site take a percentage of revenue, and Rimo and Aesthera are the two that explicitly do not. If you have already decided against revenue shares, both of these remain on the list and the others do not.
The number missing from Rimo's page
Rimo states a flat fee. It does not state the amount.
Aesthera's is $497 a month. Without Rimo's figure there is nothing to put beside it, so the first question is simply what the flat fee is.
Then ask whether a per-order or per-patient charge sits alongside it. Flat pricing and no per-patient charge are separate claims, and a platform can honestly make the first while still charging the second.
D2C brands are not med spas
Rimo describes itself as the operating system for D2C telehealth brands. Its copy does not mention med spas at all.
A D2C brand acquires patients online and ships to them. A med spa has a physical location, a local patient base, existing in-clinic treatments and staff who know those patients. The intake, the attribution and the retention tooling differ.
Rimo may serve med spas well. Its site is not written for them, and that is a caution rather than a verdict.
Where the menus overlap
Rimo's stated programmes are GLP-1, longevity, NAD and peptide. Aesthera's are weight management, testosterone therapy, hair loss, HRT for women, peptide therapy, and skin and aging.
Weight management and peptides overlap directly. NAD and longevity sit closer to Aesthera's skin and aging line than to anything else. Hair loss, testosterone and HRT for women appear on Aesthera's list and not on Rimo's.
What Rimo says that is worth checking
Two of Rimo's claims are unusually specific: that payment reaches your bank before the platform's, and that you own the patients and the data.
Both are worth asking Aesthera about too, and worth getting in writing from whoever you choose. Payment timing and data ownership are the two things that are hardest to recover once you have built a patient list on a platform.
What no revenue share is worth over five years
This is the quiet advantage both platforms share, and it compounds.
A commission model takes a percentage of every sale, forever. Ten percent of a growing revenue line is not a fixed cost, it is a partner who never contributed capital.
At $50,000 a month in programme revenue, a 15% commission is $7,500 a month. At $200,000 it is $30,000. A flat fee stays where it started.
If you expect to grow, the flat model is worth more each year. That is the argument for choosing either of these two over a commission platform, before you compare them to each other.
Running a clinic is not running a D2C brand
A D2C telehealth brand acquires a stranger online, converts them on a landing page, and ships to them. The patient never visits.
A med spa has a physical location, staff who know the patients, and existing treatments that bring people through the door. Prescription programmes are an addition to that relationship, not the whole of it.
That difference shows up in intake, in attribution, and in retention. A D2C platform optimises for paid acquisition. A med spa platform optimises for the patient already standing in front of you.
Rimo is built for the first. If you are the second, the tooling may fit less well than the pricing model suggests.
Interrogating the payment claim
Rimo states that payment reaches your bank before the platform's. That is a specific and checkable claim, and it is worth more than it sounds.
Platforms that act as merchant of record hold funds, sometimes for weeks, and a held balance is working capital you have financed for someone else.
Ask both vendors three things: who is the merchant of record, how long settlement takes, and whether balances can be held or reserved. A reserve is common in this category and it is the term most likely to appear after you sign rather than before.
Which one, then?
If you are a D2C brand selling weight loss and longevity, Rimo is built for you and its stated ownership terms are strong. Ask for the flat fee and the per-order position, then compare.
If you are a med spa, the model you want is the one Rimo uses, and Aesthera uses it too. Its amount is published and it is built for your category. The decision comes down to whether Rimo's unpublished number comes in below $497.
Does Rimo publish its pricing?
It states that it charges a flat fee with no revenue share, but does not publish the amount. Ask for it directly.
Do Rimo and Aesthera both avoid revenue shares?
Yes. Both state a flat fee and no revenue share, which distinguishes them from platforms that take a percentage of revenue.
Do you own your patients on Rimo?
Rimo states that you own the patients and the patient data, and that payment settles to your bank first. Get it in writing from any platform you choose.
Does Rimo work for med spas?
It markets to D2C telehealth brands and does not mention med spas. Confirm it fits a physical clinic with a local patient base before proceeding.
Which programmes does Rimo offer?
GLP-1, longevity, NAD and peptide. Aesthera adds hair loss, testosterone therapy and HRT for women.
See if Aesthera fits your med spa
Tell us which programs you want and how many patients you expect. We will map the compliant path to launch.